Spots Global Cancer Trial Database for Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
Official Title: Phase II Study Open, Not Randomized to Evaluate the Efficacy and Safety of Neoadjuvant Treatment With Gemcitabine and Erlotinib Followed by Gemcitabine, Erlotinib and Radiotherapy in Patients With Resectable Pancreatic Adenocarcinoma
Study ID: NCT01389440
Conditions
Interventions
Study Description
Brief Summary: This is a Phase II open study, not randomized with a neoadjuvant therapy,combination of Gemcitabine (1,000 mg/m2/week) with Erlotinib (100mg/day) (3 cycles of 4 weeks), followed by gemcitabine (300 mg/m2/week) combined with Erlotinib (100mg/day) and radiotherapy (45 Gy / day fr180 cGy) (5 cycles of 1 week) in patients with resectable pancreatic adenocarcinoma to assess the percentage of R0 resections. They have planned a total of 21 visits.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Clínica Universitaria de Navarra, Pamplona, Navarra, Spain
Hospital del Mar, Barcelona, , Spain
Institut Català d'Oncologia (ICO) de L'Hospitalet, Barcelona, , Spain
Hospital Vall d'Hebron, Barcelona, , Spain
Hospital Clínic de Barcelona, Barcelona, , Spain
Hospital Santa Creu y Sant Pau, Hospital Sant Pau, Barcelona, , Spain
Instituto Catalán de Oncología, Girona, , Spain
Hospital Virgen de la Arrixaca, Murcia, , Spain
Hospital la Fe de Valencia, Valencia, , Spain
Clínico Universitario de Valencia, Valencia, , Spain
Contact Details
Name: Joan Maurel, MD
Affiliation: Hospital Clinic of Barcelona
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
